Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1971 Oct;34(5):502–507. doi: 10.1136/jnnp.34.5.502

Psychiatric aspects in Parkinsonism treated with L-dopa

António R Damásio 1,2, João Lobo-Antunes 1,2, Carlos Macedo 1,2
PMCID: PMC493859  PMID: 5127432

Abstract

Psychiatric aspects of patients with Parkinsonism treated with L-dopa are described. These include acute psychosis in patients with or without previous psychiatric illness and worsening or improvement of pre-existing psychiatric conditions. Therapeutic management is discussed The relevance of these studies to the understanding of the psychiatric aspects of Parkinsonism in general is discussed.

Full text

PDF
502

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Calne D. B., Stern G. M., Laurence D. R., Sharkey J., Armitage P. L-dopa in postencephalitic parkinsonism. Lancet. 1969 Apr 12;1(7598):744–746. doi: 10.1016/s0140-6736(69)91751-6. [DOI] [PubMed] [Google Scholar]
  2. Calne D. B., Stern G. M., Spiers A. S., Laurence D. R. L-dopa in idiopathic parkinsonism. Lancet. 1969 Nov 8;2(7628):973–976. doi: 10.1016/s0140-6736(69)90536-4. [DOI] [PubMed] [Google Scholar]
  3. Celesia G. G., Barr A. N. Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol. 1970 Sep;23(3):193–200. doi: 10.1001/archneur.1970.00480270003001. [DOI] [PubMed] [Google Scholar]
  4. Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
  5. Damásio A. R., Antunes J. L., Macedo C. L-dopa, parkinsonism, and depression. Lancet. 1970 Sep 19;2(7673):611–612. doi: 10.1016/s0140-6736(70)90199-6. [DOI] [PubMed] [Google Scholar]
  6. Goodwin F. K., Brodie H. K., Murphy D. L., Bunney W. E., Jr Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients. Lancet. 1970 May 2;1(7653):908–911. doi: 10.1016/s0140-6736(70)91044-5. [DOI] [PubMed] [Google Scholar]
  7. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  8. Jenkins R. B., Groh R. H. Mental symptoms in Parkinsonian patients treated with L-dopa. Lancet. 1970 Jul 25;2(7665):177–179. doi: 10.1016/s0140-6736(70)92535-3. [DOI] [PubMed] [Google Scholar]
  9. Matussek N., Benkert O., Schneider K., Otten H., Pohlmeier H. L-dopa plus decarboxylase inhibitor in depression. Lancet. 1970 Sep 26;2(7674):660–661. doi: 10.1016/s0140-6736(70)91425-x. [DOI] [PubMed] [Google Scholar]
  10. McDowell F., Lee J. E., Swift T., Sweet R. D., Ogsbury J. S., Kessler J. T. Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa). Ann Intern Med. 1970 Jan;72(1):29–35. doi: 10.7326/0003-4819-72-1-29. [DOI] [PubMed] [Google Scholar]
  11. Randrup A., Munkvad I. Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia. 1967;11(4):300–310. doi: 10.1007/BF00404607. [DOI] [PubMed] [Google Scholar]
  12. Randrup A. Role of brain dopamine in the antipsychotic effect of neuroleptics. Evidence from studies of amphetamine-neuroleptic interaction. Mod Probl Pharmacopsychiatry. 1970;5:60–65. [PubMed] [Google Scholar]
  13. Sacks O. W., Messeloff C., Schartz W., Goldfarb A., Kohl M. Effects of L-dopa in patients with dementia. Lancet. 1970 Jun 6;1(7658):1231–1231. doi: 10.1016/s0140-6736(70)91820-9. [DOI] [PubMed] [Google Scholar]
  14. Schwab R. S., Zieper I. Effects of mood, motivation, stress and alertness on the performance in Parkinson's disease. Psychiatr Neurol (Basel) 1965;150(6):345–357. doi: 10.1159/000127780. [DOI] [PubMed] [Google Scholar]
  15. TALLAND G. A. Cognitive function in Parkinson's disease. J Nerv Ment Dis. 1962 Sep;135:196–205. [PubMed] [Google Scholar]
  16. Webster D. D. Critical analysis of the disability in Parkinson's disease. Mod Treat. 1968 Mar;5(2):257–282. [PubMed] [Google Scholar]
  17. Yahr M. D., Duvoisin R. C., Schear M. J., Barrett R. E., Hoehn M. M. Treatment of parkinsonism with levodopa. Arch Neurol. 1969 Oct;21(4):343–354. doi: 10.1001/archneur.1969.00480160015001. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES